ANTCHAIN
1.11.2021 07:05:09 CET | Business Wire | Press release
Blockchain Association Singapore (BAS) today signed a Memorandum of Understanding (MOU) with AntChain, the flagship technology brand of Ant Group to form close collaborations to promote and drive further blockchain adoption and innovation in Singapore and ASEAN.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20211031005054/en/
Under the partnership, BAS and AntChain will co-organize events and programs in Singapore and China to raise further awareness of blockchain, to drive industry adoption and promote positive impact through continuous innovation, and to strengthen the ecosystem of talents and empower the community through training and knowledge sharing.
The MOU with BAS is the first such industry partnership for AntChain outside China.
Commenting on the partnership, Mr Chia Hock Lai, Co-Chairman, BAS said, “We recognize AntChain’s market leadership as demonstrated through its innovative solutions and a vast range of industry applications and use cases from supply chain finance, cross border traceability of high value goods, to content and copyright protection. Thus, it is an absolute pleasure to collaborate closely with AntChain, which we believe will bring valuable technical know-how and industry experience to BAS’s members and partners in Singapore and the region. Together, more blockchain innovations can be fostered to contribute to the growth and transformation of businesses and industries.”
Mr Derrick Loi, General Manager of International Business, Intelligent Technology at Ant Group, echoed, “We firmly believe that partnerships and collaborations stimulate innovation. We are committed to working closely with industry partners such as BAS to explore new synergies, resolve pain points faced by businesses, and uncover greater value for a broader group of customers in today's digital economy. We very much look forward to enabling trusts in use cases such as digital trade, thereby connecting B2B2C with industry specific applications of enterprise blockchain, secure computing, IoT, eKYC, and other innovative technologies.”
In recent months, BAS has also formed partnerships with Alliance of Blockchain Industry (ABI) and the Energy Research Institute of the Nanyang Technological University respectively, to collaborate in various aspects to promote blockchain application, research and talent development.
In June, AntChain launched a developer community support program at its first developer conference. To date, the community has attracted over 330 institutional partners and nearly 10,000 developers, who together have created over 30 innovative industry applications. Now AntChain's wide portfolio of technologies and solutions have been deployed in more than 50 use cases, typically involving multi-party collaborations.
+++
About Blockchain Association Singapore
The Blockchain Association Singapore (BAS) seeks to empower its members and the community to leverage blockchain and scalable technologies for business growth and transformation. The Association is designed to be an effective platform for members to engage with multiple stakeholders – both regional and international – to discover solutions and promote best practices in a collaborative, open, and transparent manner.
It aims to promote blockchain literacy and build a strong talent pipeline for the digital economy in Singapore. BAS also aims to accelerate the development of blockchain companies operating in or entering into Singapore, and their subsequent integration and acceleration into the Singapore blockchain ecosystem.
For more information, please visit https://singaporeblockchain.org/ .
About AntChain
As the flagship technology brand of Ant Group, AntChain is dedicated to building the foundations of trust with innovative technologies including blockchain, the internet of things, data analytics, and intelligent risk management. It aims to develop mutually trusted, highly efficient industry based solutions to enable trust between enterprises and their customers in the new digital economy, support industry collaboration and value creation. AntChain was ranked first in China's blockchain-as-a-service market in 2020, according to market intelligence provider IDC.
View source version on businesswire.com: https://www.businesswire.com/news/home/20211031005054/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Datroway® Approved in the EU as Only TROP2 Directed Medicine with Overall Survival Benefit for the First-Line Treatment of Patients with Metastatic TNBC Who Are Not Candidates for Immunotherapy31.7.2026 08:30:00 CEST | Press release
Approval based on TROPION-Breast02 phase 3 trial results where Daiichi Sankyo and AstraZeneca’s Datroway showed a statistically significant and clinically meaningful improvement for the dual primary endpoints of overall survival and progression-free survival Datroway now approved for two breast cancer indications in the EU Datroway® (datopotamab deruxtecan) has been approved in the European Union (EU) as monotherapy for the first-line treatment of adult patients with unresectable or metastatic triple negative breast cancer (TNBC) who are not candidates for PD-1/PD-L1 inhibitor therapy. Datroway is a specifically engineered TROP2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The approval by the European Commission follows the positive opinionof the Committee for Medicinal Products for Human Use of the European Medicines Agency and is based on result
Polpharma Biologics Announces FDA and EMA Acceptance for Review of PB016 Vedolizumab Biosimilar Candidate31.7.2026 08:30:00 CEST | Press release
Polpharma Biologics International AG today announces that the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted for review the Biologics License Application (BLA) and Marketing Authorisation Application (MAA), respectively, for PB016, a proposed vedolizumab biosimilar candidate to Takeda’s reference product Entyvio®* (vedolizumab) lyophilized vial for intravenous (IV) administration for the treatment of adults with moderately to severely active ulcerative colitis and Crohn's disease. The BLA and MAA acceptances represent significant milestones in Polpharma Biologics' development program and underscore the company's commitment to advancing high-quality biosimilars and expanding global access to affordable biologic medicines. "FDA and EMA acceptances for review of our IV vedolizumab biosimilar candidate mark a major achievement for Polpharma Biologics and validate our deep scientific expertise in biosimilar development and manufacturing," said
SES: Disclosure of Share Buyback Transactions31.7.2026 07:30:00 CEST | Press release
In the time period from June 2, 2026 until and including June 23, 2026, a number of 213,167 shares were bought back within the framework of the share buyback of SES to meet obligations under SES’s Equity Based Compensation Plan (EBCP). Shares were bought back as follows: Day of purchase Aggregated volume in shares Daily weighted average acquisition price of shares (EUR) Market June 2, 2026 27,097 8.8727 DXE June 2, 2026 72,903 8.8556 ENX June 5, 2026 16,624 8.3723 DXE June 5, 2026 31,510 8.4266 ENX June 15, 2026 26,451 7.8423 XPAR June 17, 2026 26,812 7.3910 XPAR June 23, 2026 11,770 7.2200 XPAR The transactions in a detailed form are published on SES’s website: https://www.ses.com/investors/shareholder-information/share-buy-backs. Follow us on: Twitter | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, busin
Half-Year Report on SES’s Liquidity Contract31.7.2026 07:30:00 CEST | Press release
Pursuant to the liquidity contract entered into by SES with BNP Paribas as of 7 April 2026, please see the below update on the progress of the liquidity services. When the liquidity services were implemented as of 7 April 2026, the following assets were in the liquidity account: € 2,500,000 As of 30 June 2026, the following assets appeared on the liquidity account: 228,186 shares; € 816,880. Over the period from 7 April 2026 to 30 June 2026, the following transactions were executed: 1,082 buy transactions; 1,308 sales transactions. Over this same period, the volumes traded represented: 1,093,335 shares and € 8,485,986 on the buy side; 873,399 shares and € 6,860,843 on the sell side. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where th
SES Publishes FY2025 EU Taxonomy Restatement31.7.2026 07:30:00 CEST | Press release
SES today published a restatement of its FY2025 EU Taxonomy (Article 8) disclosure. The restatement updates the FY2025 EU Taxonomy disclosure included in the 2025 Annual Report and supersedes the previously published disclosure. The FY2025 EU Taxonomy Restatement is available on the SES website: https://www.ses.com/sites/ses_v2/files/investor-files/2026-07/EU_Taxonomy_Report_Restatement_2025.pdf Follow us on: X | Facebook | YouTube | LinkedIn | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer more than 100 years of combined global industry l
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom